| | 修订前 | | 修订后 | | --- | --- | --- | --- | | 第五条 | 公司住所：西藏山南市泽当镇三湘大道 | 第五条 | 公司住所：西藏自治区山南市乃东区产城 | | 17 | 号；邮政编码：856000。 | 一体示范园区 | A-04-04 号；邮政编码：856000 | 除上述内容外，《公司章程》其他内容不变。 本次修订《公司章程》尚需提交公司股东会审议，并经出席股东 会有效表决权股份总数的三分之二以上通过。 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 8 日召开的第五届董事会第三十四次会议审议通过了《关于修订 <公司章程>的议案》。公司拟对《公司章程》部分条款进行修订，具 体修订内容如下： 公司章程修订对照表 特此公告。 证券代码：002653 证券简称：海思科 公告编号：2026-006 海思科医药集团股份有限公司 1 海思科医药集团股份有限公司董事会 2026 年 1 月 10 日 ...

海思科医药集团股份有限公司 关于与 AirNexis 签署 HSK39004 项目 授权许可协议暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 风险提示： 本次交易许可协议中所约定的首付款和里程碑款等款项需要满 足一定的条件，交易最终能否实施尚存在不确定性。 证券代码：002653 证券简称：海思科 公告编号：2026-008 一、交易概述 （一）海思科医药集团股份有限公司（以下简称"海思科"或"公 司"）与美国 AirNexis Therapeutics, Inc.（曾用名 Dragonwell Biosciences, Inc.，以下简称"AirNexis"）签订独占许可协议（以 下简称"许可协议")，授予 AirNexis 在除中国大陆、香港特别行政 区、澳门特别行政区及台湾地区以外的全球范围内开发、生产和商业 化 HSK39004 的独家权利。AirNexis 将向海思科支付 1.08 亿美元首 付款（含 4,000 万美元现金及等值约 6,800 万美元的 AirNexis 公司 19.9%股权）及最高 9.55 亿美元的额外里程碑 ...

证券代码：002653 证券简称：海思科 公告编号：2026-007 海思科医药集团股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 8 日召开的第五届董事会第三十四次会议审议通过了《关于使用 闲置募集资金进行现金管理的议案》，同意公司在确保不影响正常运 营和募集资金投资项目建设的情况下，使用暂时闲置的募集资金不超 过人民币 2.3 亿元进行现金管理，保荐机构出具了核查意见。现将相 关情况公告如下： 一、 募集资金基本情况 会拟将"盐酸乙酰左卡尼汀片的中国上市后再评价项目"节余募集资 金 1,641.52 万元用于永久补充流动资金； "长效口服降血糖新药 HSK-7653 的中国Ⅲ期临床研究及上市注册项目"中部分节余募集资 金 5301.75 万元用于"新型外周神经痛治疗药物 HSK16149 胶囊（中 文通用名：苯磺酸克利加巴林胶囊）的中国Ⅲ期临床研究及上市注册 项目"；剩余的节余募集资金将根据自身发展规划及实际生产经营需 求，围绕主业 ...

证券代码：002653 证券简称：海思科 公告编号：2026-005 海思科医药集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 28 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 01 月 28 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2026 年 01 月 28 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 ...

证券代码：002653 证券简称：海思科 公告编号：2026-004 海思科医药集团股份有限公司 第五届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）第五届董事 会第三十四次会议（以下简称"会议"）于 2026 年 1 月 8 日以通讯 表决方式召开。会议通知于 2026 年 1 月 4 日以专人送达方式发出。 会议应出席董事 5 人，以通讯表决方式出席董事 5 人。会议由公司董 事长王俊民先生召集并主持。本次会议的通知、召开以及参与表决董 事人数均符合有关法律、法规、规则及《公司章程》的有关规定。全 体董事经过审议，以投票表决方式通过了如下决议： 一、审议通过了《关于修订<公司章程>的议案》 表决结果：5 票同意、0 票弃权、0 票反对。 详见同日刊登在巨潮资讯网等公司指定信息披露媒体的《关于修 订<公司章程>的公告》。 该议案尚需公司股东会以特别决议方式审议通过。 二、审议通过了《关于使用闲置募集资金进行现金管理的议案》 表决结果：5 票同意、0 票弃权、0 票反对 董事会同意公 ...

海思科公告称，公司2020年非公开发行股票募集资金净额7.91亿元，募投项目已整体结项。公司拟 将"盐酸乙酰左卡尼汀片的中国上市后再评价项目"节余募集资金1641.52万元永久补充流动资金；"长效 口服降血糖新药HSK - 7653项目"部分节余5301.75万元用于"新型外周神经痛治疗药物HSK16149胶囊项 目"。截至2025年12月31日，募集资金专户余额2.26亿元。为提高资金使用效率，公司拟自2026年2月10 日起12个月内，使用不超2.3亿元闲置募集资金进行现金管理，资金可循环滚动使用。该事项已获董事 会等审议通过，保荐机构无异议。 ...

海思科公告称，公司与AirNexis签订独占许可协议，授予其在除中国部分地区外全球开发、生产和商业 化HSK39004的独家权利。AirNexis将支付1.08亿美元首付款（含4000万美元现金及约6800万美元等值股 权）及最高9.55亿美元额外里程碑付款、特许权使用费，若再许可，海思科还有分成。公司董事长王俊 民参与AirNexis 2亿美元投资，出资500万美元占1.4%股权，本次交易构成关联交易，尚需股东会批准。 ...

Group 1 - The core viewpoint of the news is that 海思科 has shown a mixed performance in stock price and financial results, with a notable increase in stock price recently but a decline in net profit year-on-year [1][2]. Group 2 - As of January 9, 海思科's stock price increased by 2.09% to 56.15 CNY per share, with a total market capitalization of 628.83 billion CNY [1]. - The company has seen a year-to-date stock price increase of 9.41%, with a 9.41% rise over the last five trading days, a 3.98% decline over the last 20 days, and an 8.13% increase over the last 60 days [1]. - For the period from January to September 2025, 海思科 reported a revenue of 3.3 billion CNY, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, while the average circulating shares per person decreased by 11.40% to 37,342 shares [2][3].

Core Viewpoint - The capital market in Tibet has made significant contributions to the high-quality development of the local economy during the "14th Five-Year Plan" period, with a focus on the dual growth of quantity and quality of listed companies, continuous innovation investment, improved investor return mechanisms, and robust risk prevention measures [1][2]. Group 1: Listed Companies' Performance - During the "14th Five-Year Plan," the number of listed companies in Tibet increased to 22, with a total market value rising from over 200 billion to 320 billion yuan, and 14 companies entering the "100 billion club," accounting for nearly 60% [7]. - The total operating revenue of these companies reached 40.98 billion yuan in the first three quarters of 2025, a year-on-year increase of 4.96%, while net profit attributable to shareholders was 6.63 billion yuan, up 37.2%, significantly outpacing national averages [7]. - The pharmaceutical and non-ferrous metal industries have emerged as the main drivers of regional economic development, with 8 pharmaceutical companies and 3 non-ferrous metal companies leading the way [7]. Group 2: Innovation and R&D - Innovation has been a core strategy for listed companies in Tibet, with R&D expenditures reaching 2.206 billion yuan in 2024, a 53.09% increase from 1.441 billion yuan in 2020, and R&D intensity rising to 4.06%, exceeding the national average by about 2 percentage points [12]. - In the first three quarters of 2025, R&D expenses totaled 1.74 billion yuan, a year-on-year increase of 18.8%, with R&D intensity reaching 4.24, nearly double the national average [12]. Group 3: Investor Returns - Listed companies in Tibet have focused on enhancing investor returns, with cumulative cash dividends during the "14th Five-Year Plan" period amounting to 17.012 billion yuan, a 28.79% increase compared to the "13th Five-Year Plan" [14]. - The stability and predictability of dividends have improved significantly, with companies like Meihua Biological achieving the highest cumulative dividends of 6.218 billion yuan during this period [14][15]. Group 4: Financing and Capital Tools - The capital market in Tibet has diversified financing tools, with direct financing amounts growing from 13.92 billion yuan in 2021 to 25.528 billion yuan in 2024, reflecting a compound annual growth rate of 22.40% [16]. - The issuance of asset-backed securities (ABS) marked a significant milestone, with a local state-owned enterprise issuing 7 ABS products in 2024, achieving a "zero breakthrough" in ABS issuance in Tibet [16]. Group 5: Risk Prevention and Regulation - Regulatory authorities in Tibet have adopted a "zero tolerance" approach to risk prevention, handling 13 cases of capital market violations during the "14th Five-Year Plan," with penalties exceeding 30 million yuan [19]. - The region has maintained a "zero default" status for corporate bonds, with no companies facing delisting risks during this period [19]. Group 6: Future Outlook - Looking ahead to the "15th Five-Year Plan," the capital market in Tibet aims to empower regional economic development through innovation, industrial upgrades, and risk prevention, with a focus on nurturing quality enterprises in sectors like pharmaceuticals and new materials [22].

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have not previously received complement inhibitors [1][2][3] Group 1: R&D Project Overview - HSK39297 is a self-developed small molecule inhibitor that blocks the activation of the alternative pathway of the complement system, targeting diseases mediated by abnormal complement activation [2] - Clinical research indicates that HSK39297 has good safety and tolerability, showing significant therapeutic advantages over eculizumab in improving anemia, reducing transfusion needs, and alleviating fatigue symptoms [2] - The drug is classified as a Class 1 chemical drug in China and is the first-tier CFB inhibitor for PNH, addressing a significant unmet clinical need with promising market prospects [2] Group 2: Regulatory Approval and Clinical Trials - The application for HSK39297 has been prioritized for review due to its classification as an innovative drug for treating urgent clinical needs and rare diseases [3] - HSK39297 is currently undergoing Phase II clinical trials for lupus nephritis and is set to initiate Phase III clinical research for primary IgA nephropathy [3]